TY - JOUR
T1 - Using Japanese big data to investigate novel factors and their high-risk combinations that affect vancomycin-induced nephrotoxicity
AU - Imai, Shungo
AU - Kadomura, Shota
AU - Miyai, Takayuki
AU - Kashiwagi, Hitoshi
AU - Sato, Yuki
AU - Sugawara, Mitsuru
AU - Takekuma, Yoh
N1 - Funding Information:
The authors thank the Health, Clinic, and Education Information Evaluation Institute, for database development for the study. This research was funded by JSPS KAKENHI (grant number JP19K23791).
Funding Information:
The authors thank the Health, Clinic, and Education Information Evaluation Institute, for database development for the study. This research was funded by JSPS KAKENHI (grant number JP19K23791).
Publisher Copyright:
© 2022 British Pharmacological Society.
PY - 2022/7
Y1 - 2022/7
N2 - Aims: Several factors related to vancomycin-induced nephrotoxicity (VIN) have not yet been clarified. In the present study, we used Japanese big data to investigate novel factors and their high-risk combinations that influence VIN. Methods: We employed a large Japanese electronic medical record database and included patients who had been administered intravenous vancomycin between June 2000 and December 2020. VIN was defined as an increase in serum creatinine ≥0.5 mg/dL or 1.5-fold higher than the baseline. The outcomes were: (1) factors affecting VIN that were identified using multiple logistic regression analysis, and (2) combinations of factors that affect the risk of VIN according to a decision tree analysis, which is a typical machine learning method. Results: Of the 7306 patients that were enrolled, VIN occurred in 14.2% of them (1035). A multivariate analysis extracted 22 variables as independent factors. Concomitant ramelteon use (odds ratio 0.701, 95% confidence interval 0.512-0.959), ward pharmacy service (0.741, 0.638-0.861), duration of VCM < 7 days (0.748, 0.623-0.899) and trough concentrations 10-15 mg/L (0.668, 0.556-0.802) reduce the risk of VIN. Meanwhile, concomitant piperacillin-tazobactam use (2.056, 1.754-2.409) and piperacillin use (2.868, 1.298-6.338) increase the risk. The decision tree analysis showed that a combination of vancomycin trough concentrations ≥20 mg/L and concomitant piperacillin-tazobactam use was associated with the highest risk. Conclusions: We revealed that the concomitant ramelteon use and ward pharmacy service may decrease the risk of VIN, while the concomitant use of not only piperacillin-tazobactam but also piperacillin may increase the risk.
AB - Aims: Several factors related to vancomycin-induced nephrotoxicity (VIN) have not yet been clarified. In the present study, we used Japanese big data to investigate novel factors and their high-risk combinations that influence VIN. Methods: We employed a large Japanese electronic medical record database and included patients who had been administered intravenous vancomycin between June 2000 and December 2020. VIN was defined as an increase in serum creatinine ≥0.5 mg/dL or 1.5-fold higher than the baseline. The outcomes were: (1) factors affecting VIN that were identified using multiple logistic regression analysis, and (2) combinations of factors that affect the risk of VIN according to a decision tree analysis, which is a typical machine learning method. Results: Of the 7306 patients that were enrolled, VIN occurred in 14.2% of them (1035). A multivariate analysis extracted 22 variables as independent factors. Concomitant ramelteon use (odds ratio 0.701, 95% confidence interval 0.512-0.959), ward pharmacy service (0.741, 0.638-0.861), duration of VCM < 7 days (0.748, 0.623-0.899) and trough concentrations 10-15 mg/L (0.668, 0.556-0.802) reduce the risk of VIN. Meanwhile, concomitant piperacillin-tazobactam use (2.056, 1.754-2.409) and piperacillin use (2.868, 1.298-6.338) increase the risk. The decision tree analysis showed that a combination of vancomycin trough concentrations ≥20 mg/L and concomitant piperacillin-tazobactam use was associated with the highest risk. Conclusions: We revealed that the concomitant ramelteon use and ward pharmacy service may decrease the risk of VIN, while the concomitant use of not only piperacillin-tazobactam but also piperacillin may increase the risk.
KW - electronic medical record database
KW - machine learning
KW - nephrotoxicity
KW - piperacillin
KW - ramelteon
KW - vancomycin
KW - ward pharmacy service
UR - http://www.scopus.com/inward/record.url?scp=85124763201&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124763201&partnerID=8YFLogxK
U2 - 10.1111/bcp.15252
DO - 10.1111/bcp.15252
M3 - Article
C2 - 35106797
AN - SCOPUS:85124763201
SN - 0306-5251
VL - 88
SP - 3241
EP - 3255
JO - British journal of clinical pharmacology
JF - British journal of clinical pharmacology
IS - 7
ER -